Literature DB >> 28530684

Tackling HIV and AIDS: contributions by non-human primate models.

Koen K A Van Rompay1.   

Abstract

During the past three decades, non-human primate (NHP) models have gained an increasing importance in HIV basic and translational research. In contrast to natural host models, infection of macaques with virulent simian or simian-human immunodeficiency viruses (SIV, SHIV) results in a disease that closely resembles HIV infection and AIDS. Although there is no perfect animal model, and each of the available models has its benefits and limitations, carefully designed NHP studies with selection of experimental variables have unraveled important questions of basic pathogenesis and have provided the tools to explore and screen intervention strategies. For example, NHP studies have advanced our understanding of the crucial events during early infection, and have provided proof-of-concept of antiretroviral drug treatment and prevention strategies such as pre-exposure prophylaxis (PrEP) regimes that are increasingly used worldwide, and upon overcoming further barriers of implementation, have the potential to make the next generation AIDS-free. Remaining goals include the pursuit of an effective HIV vaccine, and HIV cure strategies that would allow HIV-infected people to ultimately stop taking antiretroviral drugs. Through a reiterative process with feed-back from results of human studies, NHP models can be further validated and strengthened to advance our scientific knowledge and guide clinical trials.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28530684     DOI: 10.1038/laban.1279

Source DB:  PubMed          Journal:  Lab Anim (NY)        ISSN: 0093-7355            Impact factor:   12.625


  145 in total

1.  Patterns of plasma human immunodeficiency virus type 1 RNA response to antiretroviral therapy.

Authors:  W Huang; V De Gruttola; M Fischl; S Hammer; D Richman; D Havlir; R Gulick; K Squires; J Mellors
Journal:  J Infect Dis       Date:  2001-04-24       Impact factor: 5.226

2.  Attenuated poxvirus-based simian immunodeficiency virus (SIV) vaccines given in infancy partially protect infant and juvenile macaques against repeated oral challenge with virulent SIV.

Authors:  Koen K A Van Rompay; Kristina Abel; Jonathan R Lawson; Raman P Singh; Kimberli A Schmidt; Thomas Evans; Patricia Earl; Danielle Harvey; Genoveffa Franchini; James Tartaglia; David Montefiori; Shilpa Hattangadi; Bernard Moss; Marta L Marthas
Journal:  J Acquir Immune Defic Syndr       Date:  2005-02-01       Impact factor: 3.731

3.  Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques.

Authors:  Daria J Hazuda; Steven D Young; James P Guare; Neville J Anthony; Robert P Gomez; John S Wai; Joseph P Vacca; Larry Handt; Sherri L Motzel; Hilton J Klein; Geethanjali Dornadula; Robert M Danovich; Marc V Witmer; Keith A A Wilson; Lynda Tussey; William A Schleif; Lori S Gabryelski; Lixia Jin; Michael D Miller; Danilo R Casimiro; Emilio A Emini; John W Shiver
Journal:  Science       Date:  2004-07-08       Impact factor: 47.728

Review 4.  Microbicides and HIV prevention: lessons from the past, looking to the future.

Authors:  Georgina C Morris; Charles J N Lacey
Journal:  Curr Opin Infect Dis       Date:  2010-02       Impact factor: 4.915

5.  Postexposure protection of macaques from vaginal SHIV infection by topical integrase inhibitors.

Authors:  Charles Dobard; Sunita Sharma; Urvi M Parikh; Rolieria West; Andrew Taylor; Amy Martin; Chou-Pong Pau; Debra L Hanson; Jonathan Lipscomb; James Smith; Francis Novembre; Daria Hazuda; J Gerardo Garcia-Lerma; Walid Heneine
Journal:  Sci Transl Med       Date:  2014-03-12       Impact factor: 17.956

6.  Experimental infection of cynomolgus monkeys (Macaca fascicularis) with HIV-2.

Authors:  P Putkonen; B Böttiger; K Warstedt; R Thorstensson; J Albert; G Biberfeld
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1989

7.  Nucleotide analogue prodrug tenofovir disoproxil enhances lymphoid cell loading following oral administration in monkeys.

Authors:  Lucie Durand-Gasselin; Koen K A Van Rompay; Jennifer E Vela; Ilana N Henne; William A Lee; Gerry R Rhodes; Adrian S Ray
Journal:  Mol Pharm       Date:  2009 Jul-Aug       Impact factor: 4.939

8.  Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis.

Authors:  Myriam Witvrouw; Christophe Pannecouque; William M Switzer; Thomas M Folks; Erik De Clercq; Walid Heneine
Journal:  Antivir Ther       Date:  2004-02

Review 9.  Feline immunodeficiency virus infection: an overview.

Authors:  K Hartmann
Journal:  Vet J       Date:  1998-03       Impact factor: 2.688

10.  TRIM5alpha Modulates Immunodeficiency Virus Control in Rhesus Monkeys.

Authors:  So-Yon Lim; Thomas Rogers; Tiffany Chan; James B Whitney; Jonghwa Kim; Joseph Sodroski; Norman L Letvin
Journal:  PLoS Pathog       Date:  2010-01-22       Impact factor: 6.823

View more
  12 in total

Review 1.  Nonhuman Primates and Translational Research: Progress, Opportunities, and Challenges.

Authors:  John D Harding
Journal:  ILAR J       Date:  2017-12-01

2.  Nonhuman Primate Models and Understanding the Pathogenesis of HIV Infection and AIDS.

Authors:  Ronald S Veazey; Andrew A Lackner
Journal:  ILAR J       Date:  2017-12-01

3.  Sequence diversity analyses of an improved rhesus macaque genome enhance its biomedical utility.

Authors:  Wesley C Warren; R Alan Harris; Marina Haukness; Ian T Fiddes; Shwetha C Murali; Jason Fernandes; Philip C Dishuck; Jessica M Storer; Muthuswamy Raveendran; LaDeana W Hillier; David Porubsky; Yafei Mao; David Gordon; Mitchell R Vollger; Alexandra P Lewis; Katherine M Munson; Elizabeth DeVogelaere; Joel Armstrong; Mark Diekhans; Jerilyn A Walker; Chad Tomlinson; Tina A Graves-Lindsay; Milinn Kremitzki; Sofie R Salama; Peter A Audano; Merly Escalona; Nicholas W Maurer; Francesca Antonacci; Ludovica Mercuri; Flavia A M Maggiolini; Claudia Rita Catacchio; Jason G Underwood; David H O'Connor; Ashley D Sanders; Jan O Korbel; Betsy Ferguson; H Michael Kubisch; Louis Picker; Ned H Kalin; Douglas Rosene; Jon Levine; David H Abbott; Stanton B Gray; Mar M Sanchez; Zsofia A Kovacs-Balint; Joseph W Kemnitz; Sara M Thomasy; Jeffrey A Roberts; Erin L Kinnally; John P Capitanio; J H Pate Skene; Michael Platt; Shelley A Cole; Richard E Green; Mario Ventura; Roger W Wiseman; Benedict Paten; Mark A Batzer; Jeffrey Rogers; Evan E Eichler
Journal:  Science       Date:  2020-12-18       Impact factor: 47.728

4.  In Vivo Validation of the Viral Barcoding of Simian Immunodeficiency Virus SIVmac239 and the Development of New Barcoded SIV and Subtype B and C Simian-Human Immunodeficiency Viruses.

Authors:  Sirish Khanal; Christine M Fennessey; Sean P O'Brien; Abigail Thorpe; Carolyn Reid; Taina T Immonen; Rodman Smith; Julian W Bess; Adrienne E Swanstrom; Gregory Q Del Prete; Miles P Davenport; Afam A Okoye; Louis J Picker; Jeffrey D Lifson; Brandon F Keele
Journal:  J Virol       Date:  2019-12-12       Impact factor: 5.103

5.  CD8+ T cells fail to limit SIV reactivation following ART withdrawal until after viral amplification.

Authors:  Afam A Okoye; Derick D Duell; Yoshinori Fukazawa; Benjamin Varco-Merth; Alejandra Marenco; Hannah Behrens; Morgan Chaunzwa; Andrea N Selseth; Roxanne M Gilbride; Jason Shao; Paul T Edlefsen; Romas Geleziunas; Mykola Pinkevych; Miles P Davenport; Kathleen Busman-Sahay; Michael Nekorchuk; Haesun Park; Jeremy Smedley; Michael K Axthelm; Jacob D Estes; Scott G Hansen; Brandon F Keele; Jeffery D Lifson; Louis J Picker
Journal:  J Clin Invest       Date:  2021-04-15       Impact factor: 14.808

6.  Dolutegravir Monotherapy of Simian Immunodeficiency Virus-Infected Macaques Selects for Several Patterns of Resistance Mutations with Variable Virological Outcomes.

Authors:  Koen K A Van Rompay; Said Hassounah; Brandon F Keele; Jeffrey D Lifson; Amir Ardeshir; Jennifer Watanabe; Hanh Thi Pham; Elena Chertova; Raymond Sowder; Jan Balzarini; Thibault Mesplède; Mark A Wainberg
Journal:  J Virol       Date:  2019-01-04       Impact factor: 5.103

7.  Overcoming immunogenicity issues of HIV p24 antigen by the use of innovative nanostructured lipid carriers as delivery systems: evidences in mice and non-human primates.

Authors:  Emilie Bayon; Jessica Morlieras; Nathalie Dereuddre-Bosquet; Alexis Gonon; Leslie Gosse; Thomas Courant; Roger Le Grand; Patrice N Marche; Fabrice P Navarro
Journal:  NPJ Vaccines       Date:  2018-10-01       Impact factor: 7.344

Review 8.  Humanized Mice for the Evaluation of Novel HIV-1 Therapies.

Authors:  Shawn Abeynaike; Silke Paust
Journal:  Front Immunol       Date:  2021-04-01       Impact factor: 7.561

9.  Infection of Chinese Rhesus Monkeys with a Subtype C SHIV Resulted in Attenuated In Vivo Viral Replication Despite Successful Animal-to-Animal Serial Passages.

Authors:  Gerald K Chege; Craig H Adams; Alana T Keyser; Valerie Bekker; Lynn Morris; Francois J Villinger; Anna-Lise Williamson; Rosamund E Chapman
Journal:  Viruses       Date:  2021-03-02       Impact factor: 5.048

10.  Tree Shrew Cells Transduced with Human CD4 and CCR5 Support Early Steps of HIV-1 Replication, but Viral Infectivity Is Restricted by APOBEC3.

Authors:  Meng-Ting Luo; Dan Mu; Xiang Yang; Rong-Hua Luo; Hong-Yi Zheng; Min Chen; Ying-Qi Guo; Yong-Tang Zheng
Journal:  J Virol       Date:  2021-07-26       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.